Earnings Yield is calculated by taking the operating income or earnings before interest and taxes (EBIT) and dividing it by the Enterprise Value of the company. The Earnings Yield for Cannabis Sativa, Inc. (OTCPK:CBDS) stands at -0.053574. Earnings Yield helps investors measure the return on investment for a given company. Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value. The Earnings Yield Five Year average for Cannabis Sativa, Inc. (OTCPK:CBDS) is -0.044033. Further, the Earnings to Price yield of Cannabis Sativa, Inc. OTCPK:CBDS is -0.059672. This is calculated by taking the earnings per share and dividing it by the last closing share price. This is one of the most popular methods investors use to evaluate a company’s financial performance.

When it comes to investing in the stock market, there are many different styles and strategies that can be used. Some investors will want to do all the work themselves to try to adopt a specific plan all their own. Others will attempt to replicate strategies that have worked for others in the past. Of course, there is no sure bet strategy that will produce instant investing success. Taking the time to study all the different investing methods may be useful for some, but not as helpful for others. What worked in the past may not work again in the future. Investors will often need to decide how much risk they are willing to take on when investing in stocks. Once the risk appetite is figured out, they may want to decide how much and how aggressive they want to invest.**Quant Signals – Value Composite, C- Score, MF Rank, M-Score, ERP5**

The Value Composite One (VC1) is a method that investors use to determine a company’s value. The VC1 of Cannabis Sativa, Inc. (OTCPK:CBDS) is 89. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. The Value Composite Two of Cannabis Sativa, Inc. (OTCPK:CBDS) is 89.

Cannabis Sativa, Inc. (OTCPK:CBDS) currently has a Montier C-score of 1.00000. This indicator was developed by James Montier in an attempt to identify firms that were altering financial numbersin order to appear better on paper. The score ranges from zero to six where a 0 would indicate no evidence of book cooking, and a 6 would indicate a high likelihood of something amiss. A C-score of -1 would indicate that there is not enough information available to calculate the score. Montier used six inputs in the calculation. These inputs included a growing difference between net income and cash flow from operations, increasing receivable days, growing day’s sales of inventory, increasing other current assets, decrease in depreciation relative to gross property plant and equipment, and high total asset growth.

The MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable company trading at a good price. The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital. The MF Rank of Cannabis Sativa, Inc. (OTCPK:CBDS) is 16708. A company with a low rank is considered a good company to invest in. The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”.

Cannabis Sativa, Inc. (OTCPK:CBDS) has an M-score Beneish of -3.600421. This M-score model was developed by Messod Beneish in order to detect manipulation of financial statements. The score uses a combination of eight different variables. The specifics of the variables and formula can be found in the Beneish paper “The Detection of Earnings Manipulation”.

The last signal we’ll look at is the ERP5 Rank. The ERP5 Rank is an investment tool that analysts use to discover undervalued companies. The ERP5 looks at the Price to Book ratio, Earnings Yield, ROIC and 5 year average ROIC. The ERP5 of Cannabis Sativa, Inc. (OTCPK:CBDS) is 18058. The lower the ERP5 rank, the more undervalued a company is thought to be.

**Volatility/PI**

Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The Volatility 12m of Cannabis Sativa, Inc. (OTCPK:CBDS) is 95.875200. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized. The lower the number, a company is thought to have low volatility. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The Volatility 3m of Cannabis Sativa, Inc. (OTCPK:CBDS) is 183.160700. The Volatility 6m is the same, except measured over the course of six months. The Volatility 6m is 138.672200.

We can now take a quick look at some historical stock price index data. Cannabis Sativa, Inc. (OTCPK:CBDS) presently has a 10 month price index of 0.61471. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 1.43151, the 24 month is 0.69900, and the 36 month is 4.09804. Narrowing in a bit closer, the 5 month price index is 1.11170, the 3 month is 1.86607, and the 1 month is currently 0.78277.

**ROIC**

The Return on Invested Capital (aka ROIC) for Cannabis Sativa, Inc. (OTCPK:CBDS) is -22.677419. The Return on Invested Capital is a ratio that determines whether a company is profitable or not. It tells investors how well a company is turning their capital into profits. The ROIC is calculated by dividing the net operating profit (or EBIT) by the employed capital. The employed capital is calculated by subrating current liabilities from total assets. Similarly, the Return on Invested Capital Quality ratio is a tool in evaluating the quality of a company’s ROIC over the course of five years. The ROIC Quality of Cannabis Sativa, Inc. (OTCPK:CBDS) is -0.069814. This is calculated by dividing the five year average ROIC by the Standard Deviation of the 5 year ROIC. The ROIC 5 year average is calculated using the five year average EBIT, five year average (net working capital and net fixed assets). The ROIC 5 year average of Cannabis Sativa, Inc. (OTCPK:CBDS) is -227.224719.

As we move closer towards the end of the year, investors might be looking over the portfolio and trying to see what has been working and what hasn’t been. Investors may be studying the most recent earnings reports of stocks they own in order to make sure that everything is still in order. Active investors might be double checking the portfolio to make sure that it is properly diversified. There might be a few adjustments that need to be made in order to keep the holdings balanced. Of course, nobody can say for sure which way the momentum will shift over the next couple of quarters, but being prepared for any situation is generally considered to be a good idea.

The Earnings to Price yield of Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) is -0.087518. This is calculated by taking the earnings per share and dividing it by the last closing share price. This is one of the most popular methods investors use to evaluate a company’s financial performance. Earnings Yield is calculated by taking the operating income or earnings before interest and taxes (EBIT) and dividing it by the Enterprise Value of the company. The Earnings Yield for Agios Pharmaceuticals, Inc. NasdaqGS:AGIO is -0.105163. Earnings Yield helps investors measure the return on investment for a given company. Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value. The Earnings Yield Five Year average for Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) is -0.043304.

Investing in the stock market will always involve some level of risk. Investors often have to determine how much they are willing to risk, and try to project what the potential reward could be. Taking on too much risk may put the average investor out of their comfort zone. Finding that sweet spot for risk appetite may help investors get on the correct path to conquering the markets. As companies continue to report quarterly earnings, investors will be watching which companies post larger than expected surprises. Analysts will also be watching the numbers closely in order to make sense of the results and update estimates accordingly.**Quant Scores/Key Ratios**

Now we’ll turn to some key quant data and ratios. The Current Ratio of Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) is 8.21. The Current Ratio is used by investors to determine whether a company can pay short term and long term debts. The current ratio looks at all the liquid and non-liquid assets compared to the company’s total current liabilities. A high current ratio indicates that the company might have trouble managing their working capital. A low current ratio (when the current liabilities are higher than the current assets) indicates that the company may have trouble paying their short term obligations.

Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO)’s Leverage Ratio was recently noted as 0.000000. This ratio is calculated by dividing total debt by total assets plus total assets previous year, divided by two. The leverage of a company is relative to the amount of debt on the balance sheet. This ratio is often viewed as one measure of the financial health of a firm.

The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years. The score is a number between one and one hundred (1 being best and 100 being the worst). The Gross Margin Score of Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) is 3.00000. The more stable the company, the lower the score. If a company is less stable over the course of time, they will have a higher score.

At the time of writing, Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) has a Piotroski F-Score of 3. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) has an M-score Beneish of -1.816689. This M-score model is a little known investment tool that was developed by Messod Beneish in order to detect manipulation of financial statements. The score uses a combination of eight different variables. The specifics of the variables and formula can be found in the Beneish paper “The Detection of Earnings Manipulation”.

The Value Composite One (VC1) is a method that investors use to determine a company’s value. The VC1 of Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) is 91. A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company. The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings. Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield. The Value Composite Two of Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) is 93.

The MF Rank (aka the Magic Formula) is a formula that pinpoints a valuable company trading at a good price. The formula is calculated by looking at companies that have a high earnings yield as well as a high return on invested capital. The MF Rank of Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) is 15972. A company with a low rank is considered a good company to invest in. The Magic Formula was introduced in a book written by Joel Greenblatt, entitled, “The Little Book that Beats the Market”.

Shifting gears, we can see that Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) has a Q.i. Value of 77.00000. The Q.i. Value ranks companies using four ratios. These ratios consist of EBITDA Yield, FCF Yield, Liquidity, and Earnings Yield. The purpose of the Q.i. Value is to help identify companies that are the most undervalued. Typically, the lower the value, the more undervalued the company tends to be.

**Price Index/Share Movement**

We can now take a quick look at some historical stock price index data. Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) presently has a 10 month price index of 0.97776. The price index is calculated by dividing the current share price by the share price ten months ago. A ratio over one indicates an increase in share price over the period. A ratio lower than one shows that the price has decreased over that time period. Looking at some alternate time periods, the 12 month price index is 1.12812, the 24 month is 1.08605, and the 36 month is 1.13766. Narrowing in a bit closer, the 5 month price index is 0.70625, the 3 month is 0.88571, and the 1 month is currently 0.95068.

Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The Volatility 12m of Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) is 52.812000. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized. The lower the number, a company is thought to have low volatility. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The Volatility 3m of Agios Pharmaceuticals, Inc. (NasdaqGS:AGIO) is 58.484700. The Volatility 6m is the same, except measured over the course of six months. The Volatility 6m is 48.966300.

Investors might be looking to rebuild the portfolio as we move into the second half of the year. New investors can be tempted to try to maximize returns by owning one specific sector or be exposed to a fairly large single investment. By diversifying the portfolio, investors might be able to protect themselves from a sudden move against the position. Finding the correct portfolio balance is how many investors choose to approach the markets. This may take some time to master, and there may be some bumps along the way. Investors managing their own money may want to make sure that they know exactly what stocks are in the portfolio at all times. Keeping tabs on portfolio performance can also be a good way to make sure that it is weighted properly.

Source link